<DOC>
	<DOCNO>NCT02129608</DOCNO>
	<brief_summary>Currently United States 97 million adult consider obese , account 33 % American adult population ( compare 22.9 % 1988 ) . Obesity , define body mass index 30.0 high , accountable 44 % diabetes , 23 % ischemic heart disease 7 % 41 % certain cancer . The Erchonia® Zerona™ 2.0 Laser ( use study ) approve FDA ( K123237 ) non-invasive dermatological aesthetic treatment use individual intend reduce circumference hip , waist , thigh . Lorcaserin selective serotonin 2C ( 5-HT ( 2C ) ) receptor agonist . The exact mechanism action know , lorcaserin believe promote satiety decrease food intake activate 5-HT ( 2C ) receptor anorexigenic pro-opiomelanocortin neuron hypothalamus . Lorcaserin approve FDA June 2012 weight management people BMI &gt; 27 kg/m2 ( overweight ) accompany weigh-related condition type 2 diabetes high blood pressure people BMI &gt; 30 kg/m2 ( obese ) . The purpose pilot study obtain preliminary data : 1 ) effectiveness combination LLLT lorcaserin reduce abdominal subcutaneous fat overweight/obese individual ; 2 ) impact LLLT inflammatory biomarkers , blood sugar , cholesterol .</brief_summary>
	<brief_title>Low Level Laser Treatment ( LLLT ) Lorcaserin Weight Management</brief_title>
	<detailed_description>This study do find effective Low Level Laser Therapy ( LLLT - Erchonia® Zerona™ 2.0 Laser ) compare Lorcaserin ( Belviq® ) help overweight people reduce weight gain - especially central body region . Subjects undergo 2 screen visit investigator take medical weight concern history ; find eligible , randomize one three group : 1 ) 12 week LLLT , 2 ) 12 week Lorcaserin , 3 ) 12 week combination Lorcaserin LLLT . Full study participation last approximately 6 month consist 10 visits- 9 clinical 1 phone call . During study subject provide weight prevention counsel ask complete 3 additional fasting blood draw . There one urine pregnancy test ( female ) begin study .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>1870 year age ; body weight great 50 kg ( 110 pound ) ; BMI 2739.9 kg/m2 ; weight concern ; motivate reduce central adiposity ; able participate fully aspect study ; understood sign study inform consent . use weight loss medication participate weight loss program within past 30 day ; currently take supplement know affect weight , garcinia cambrogia . weight fluctuation 20 pound past 6 month ( selfreport ) ; implant device ( include pacemaker lap band ) target area LLLT ; active untreated clinically significant psychiatric condition ( psychosis , bipolar disorder , depression ) ; use investigational drug within 30 day study enrollment ; recent history ( past 30 day ) alcohol drug abuse dependence ; currently pregnant lactate , childbearing potential likely become pregnant medication phase unwilling use reliable form contraception ; history major cardiovascular event include heart valve disease , cardiac arrhythmia , congestive heart failure , acute coronary syndrome , stroke , transient ischemic attack , peripheral vascular disease ; current uncontrolled hypertension ( systolic &gt; 165 mm Hg diastolic &gt; 95 mm Hg ) document 2 separate occasion ; clinically significant acute chronic progressive unstable neurologic , hepatic , renal , cardiovascular , lymphatic , respiratory , metabolic disease ( diabetes ) active cancer within 1 year cancer remission ; Prior surgical intervention body sculpting/weight loss , liposuction , abdominoplasty , stomach stapling , lap band surgery , etc . ; medical , physical , contraindication body sculpting/weight loss ; current use medication ( ) know affect weight levels/cause bloat swell abstinence course study participation safe medically prudent ; concurrently take serotonergic drug ( selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAOIs ) , triptans , bupropion , dextromethorphan , St. John 's Wort ) . These drug use treat depression and/or migraine contraindicate lorcaserin ; medical condition know affect weight level and/or cause bloating swell ; diagnosis , and/or take medication , irritable bowel syndrome ; active infection , wound external trauma area treat laser ; know photosensitivity disorder ; allergic lorcaserin ; current active cancer currently receive treatment cancer ; know history condition factor judge investigator preclude participation study might hinder adherence ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>overweight</keyword>
	<keyword>obese</keyword>
	<keyword>central adiposity</keyword>
	<keyword>Laser</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>low level laser therapy</keyword>
	<keyword>belviq</keyword>
</DOC>